AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04066881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control PrEP:TDF/FTC once daily (weeks 0-26)
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study NCT04066881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study NCT04066881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study NCT04066881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study NCT01089101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01089101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 400 mg
Description: Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 40 mg
Description: Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 100 mg
Description: Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 200 mg
Description: Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 400 mg
Description: Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group A, C, W-135, and Y conjugate vaccine
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-Hib vaccine
Description: Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-HB-Hib vaccine
Description: Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (13-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (10-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine (10-valent)
Description: Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Description: Measles, mumps, and rubella vaccine
Study NCT03547271 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Description: Measles, mumps, and rubella vaccine
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 AA mg
Description: Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
Study NCT03212274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT03212274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03212274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03212274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI
Study NCT03212274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 BB mg
Description: Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 CC mg
Description: Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 DD mg
Description: Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 EE mg
Description: Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589354 YY mg
Description: Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 300 mg
Description: Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC310911 600 mg
Description: Participants will receive TMC310911 600 mg in Panel 7.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
Study NCT00333710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Description: Individual face-to-face contact with educational and goal setting components
Study NCT00333710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: Individual telephone contact with educational and goal setting components
Study NCT03420339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant
Description: The stimulants used must meet FDA dosage guidelines for age.
Study NCT01735149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kochujang Pills
Description: Kochujang Pills (34.5g/day)
Study NCT01735149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (34.5g/day)
Study NCT01707888 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracoscopy/VATS
Description: Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
Study NCT04385433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPERIMENTAL ARM
Description: Patients in the experimental arm will receive:~* Daily pravastatin (40mg/d) during 12 months (pravastatin initiation: first day of radiotherapy).~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions).
Study NCT04385433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL GROUP
Description: Patients in the standard arm will receive:~* Daily placebo during 12 months (placebo initiation: first day of radiotherapy)~* Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions).
Study NCT04385433 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)
Description: Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
Study NCT04385433 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard adjuvant whole breast radiotherapy (50Gy/ 25 fractions to whole breast) followed or not by a boost to tumor bed (16Gy/ 8 fractions)
Description: Radiotherapy will last 5 weeks during treatment by Pravastatine or Placebo
Study NCT04423640 — intervention group
Intervention type: OTHER
Intervention: Active COVID-19 disease
Description: Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
Study NCT01115777 — intervention group
Intervention type: OTHER
Intervention: Quality of Life surveys completed at specified timepoints
Description: Quality of Life surveys (no treatment)
Study NCT01992913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated Cognitive Behavioral Therapy
Description: Novel CBT paradigm for schizophrenia/schizoaffective disorder
Study NCT01992913 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
Study NCT01992913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation (CCR)
Description: Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
Study NCT04575441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with pilates ball
Description: Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
Study NCT02975817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hibler's
Description: Passive body heat retention using multiple-layer tight wrapping of patient
Study NCT02975817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm Air
Description: Active, convective warming of patient using warm air blanket
Study NCT01264809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific consultation for physical activity counseling
Description: Specific consultation
Study NCT01264809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation for physical activity counseling
Description: Specific consultation
Study NCT01945983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early norepinephrine
Description: Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
Study NCT01945983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
Study NCT02899247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surface sealant
Description: Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~* The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA).
Study NCT02899247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No surface sealant
Description: Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).
Study NCT02908984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific neck rehabilitation
Description: Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
Study NCT02908984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard primary health care
Description: The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
Study NCT00713271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Low dose~Dry powder for inhalation, o.d., 1+12 days
Study NCT00713271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00713271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: intermediate dose~Dry powder for inhalation, o.d., 1+12 days
Study NCT00713271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: high dose~Dry powder for inhalation, o.d., 1+12 days
Study NCT01105312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study NCT03043872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
Study NCT01105312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Study NCT01105312 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Study NCT01105312 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study NCT01105312 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT01105312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Study NCT01105312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT01105312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00887705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADL training
Description: The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
Study NCT01602796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School intervention
Description: The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
Study NCT04224025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and respiratory therapy
Description: three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
Study NCT00402727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
Study NCT00402727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
Description: Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
Study NCT05868538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum calprotectin and IMA concentrations
Description: Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.
Study NCT03568578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
Study NCT03568578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
Study NCT03568578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anluohuaxian Pill 12g
Description: Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
Study NCT00751140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Dissection
Description: The lymph nodes will be sent to pathology for review.
Study NCT01345656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
Study NCT00977574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01345656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
Study NCT01345656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: One 10 mg BAY94-8862 tablet for duration of 4 weeks
Study NCT01345656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
Study NCT01345656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for duration of 4 weeks
Study NCT01345656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
Study NCT01628848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study NCT00977574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00977574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study NCT00977574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00977574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00977574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT01628848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch
Study NCT02864732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises
Study NCT02864732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation